% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Alexopoulos:140054,
author = {Alexopoulos, Panagiotis and Thierjung, Nathalie and
Grimmer, Timo and Ortner, Marion and Economou, Polychronis
and Assimakopoulos, Konstantinos and Gourzis, Philippos and
Politis, Antonios and Perneczky, Robert and Initiative, The
Alzheimer’s Disease Neuroimaging},
title = {{C}erebrospinal {F}luid {BACE}1 {A}ctivity and s{A}β{PP}β
as {B}iomarker {C}andidates of {A}lzheimer's {D}isease.},
journal = {Dementia and geriatric cognitive disorders},
volume = {45},
number = {3-4},
issn = {1420-8008},
address = {Basel},
publisher = {Karger},
reportid = {DZNE-2020-06376},
pages = {152-161},
year = {2018},
abstract = {The utility of β-site amyloid-β precursor protein (AβPP)
cleaving enzyme 1 (BACE1) activity and soluble AβPP β
(sAβPPβ) levels in cerebrospinal fluid (CSF) in detecting
Alzheimer's disease (AD) is still elusive.BACE1 activity and
sAβPPβ concentration were measured in patients with AD
dementia (n = 56) and mild cognitive impairment (MCI) due to
AD (n = 76) with abnormal routine AD CSF markers, in
patients with MCI with normal CSF markers (n = 39), and in
controls without preclinical AD (n = 48). In a subsample
with available 18F-fluorodeoxyglucose positron emission
tomography (FDG PET) data, ordinal regression models were
employed to compare the contribution of BACE1 and sAβPPβ
to correct diagnostic classification to that of FDG
PET.BACE1 activity was significantly higher in patients with
MCI due to AD compared to both controls and patients with
MCI with normal CSF markers. sAβPPβ did not differ between
any of the studied groups. Interestingly, BACE1 activity was
not found to be inferior to FDG PET as predictive covariate
in differentiating between the diagnostic groups.Further
studies using biomarker-underpinned diagnoses are warranted
to shed more light on the potential diagnostic utility of
BACE1 activity as AD biomarker candidate in MCI.},
keywords = {Aged / Alzheimer Disease: cerebrospinal fluid / Alzheimer
Disease: diagnosis / Amyloid Precursor Protein Secretases:
cerebrospinal fluid / Amyloid beta-Protein Precursor:
cerebrospinal fluid / Aspartic Acid Endopeptidases:
cerebrospinal fluid / Biomarkers: cerebrospinal fluid /
Cognitive Dysfunction: cerebrospinal fluid / Cognitive
Dysfunction: diagnosis / Diagnosis, Differential / Female /
Fluorodeoxyglucose F18: pharmacology / Humans / Male /
Middle Aged / Positron-Emission Tomography: methods /
Radiopharmaceuticals: pharmacology / Amyloid beta-Protein
Precursor (NLM Chemicals) / Biomarkers (NLM Chemicals) /
Radiopharmaceuticals (NLM Chemicals) / Fluorodeoxyglucose
F18 (NLM Chemicals) / Amyloid Precursor Protein Secretases
(NLM Chemicals) / Aspartic Acid Endopeptidases (NLM
Chemicals) / BACE1 protein, human (NLM Chemicals)},
cin = {Clinical Dementia Research München},
ddc = {610},
cid = {I:(DE-2719)1111016},
pnm = {344 - Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29788013},
doi = {10.1159/000488481},
url = {https://pub.dzne.de/record/140054},
}